Content area
Abstract
In recent years, industry has reduced its investment in U.S. biomedical research and development by billions of dollars, while increasing investment in Asia–Oceania. Thus, boosting U.S. government funding alone may be inadequate for retaining long-term R&D leadership.
Details
1 From Thomas, McNerney & Partners, La Jolla, CA (J.C.); the Robert Wood Johnson Foundation Clinical Scholars Program (G.H.S., R.J.), the Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System (G.H.S.), the Center for Bioethics and Social Sciences in Medicine (R.J.), and the Departments of Otolaryngology–Head and Neck Surgery (G.H.S.) and Radiation Oncology (R.J.), University of Michigan Health System — all in Ann Arbor; the Singapore Bioimaging Consortium, Agency for Science, Technology, and Research, Singapore (J.D.S.); and the Department of Health Care Management, Wharton School, University of Pennsylvania, Philadelphia (S.M.S.).